Want to see TSE:DMED full AI Analyst Report?
DMED Stock Chart & Stats
C$0.05
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.05
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.25
Previous CloseN/A
Volume16.98K
Average Volume (3M)717.73K
Market Cap
C$7.24M
Enterprise ValueC$4.90
Total Cash (Recent Filing)C$385.75K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding131,559,310
10 Day Avg. Volume538,664
30 Day Avg. Volume717,725
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-21.78
Price to Sales (P/S)0.00
P/FCF Ratio-29.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtAbsence of financial debt lowers fixed financing costs and interest exposure, preserving cash for R&D or commercialization. Over a 2–6 month horizon this enhances survival flexibility, reduces bankruptcy risk, and allows management to prioritize product development instead of servicing lenders.
AI-enabled Medical Technology FocusA strategic focus on AI-integrated medical tech aligns with durable industry secular trends: rising digital health adoption, regulatory acceptance, and demand for diagnostic automation. This structural positioning can support scalable product offerings and long-term market relevance if commercialization succeeds.
Improving Cash Burn TrendA measurable reduction in operating cash outflows signals improving cost control or operating efficiency. If sustained, lower burn extends runway, reduces near-term financing needs, and gives management more time to reach commercial milestones or secure strategic partnerships.
Bears Say
Pre-revenue StatusNo revenue base means no proven commercial product-market fit and limited internal cash generation. Over months this keeps the company dependent on external funding to sustain operations and delays validation of unit economics and scalable margins.
Negative Stockholders' EquityAccumulated deficits that produced negative equity signal persistent losses and weaken the balance sheet. This constrains financing options, increases dilution risk if equity raises are needed, and reduces creditor confidence over a multi-month horizon.
Consistent Negative Cash FlowSustained negative operating and free cash flow implies the company cannot self-fund operations or growth. In the medium term this increases execution risk, forces capital raises that dilute shareholders, and limits ability to scale until profitable or cash-flow positive.
DiagnaMed Holdings Corp. News
DMED FAQ
What was DiagnaMed Holdings Corp.’s price range in the past 12 months?
DiagnaMed Holdings Corp. lowest stock price was C$0.03 and its highest was C$0.25 in the past 12 months.
What is DiagnaMed Holdings Corp.’s market cap?
DiagnaMed Holdings Corp.’s market cap is C$7.24M.
When is DiagnaMed Holdings Corp.’s upcoming earnings report date?
DiagnaMed Holdings Corp.’s upcoming earnings report date is Feb 02, 2027 which is in 182 days.
How were DiagnaMed Holdings Corp.’s earnings last quarter?
DiagnaMed Holdings Corp. released its earnings results on Jul 29, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is DiagnaMed Holdings Corp. overvalued?
According to Wall Street analysts DiagnaMed Holdings Corp.’s price is currently Overvalued.
Does DiagnaMed Holdings Corp. pay dividends?
DiagnaMed Holdings Corp. does not currently pay dividends.
What is DiagnaMed Holdings Corp.’s EPS estimate?
DiagnaMed Holdings Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DiagnaMed Holdings Corp. have?
DiagnaMed Holdings Corp. has 131,559,310 shares outstanding.
What happened to DiagnaMed Holdings Corp.’s price movement after its last earnings report?
DiagnaMed Holdings Corp. reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DiagnaMed Holdings Corp.?
Currently, no hedge funds are holding shares in TSE:DMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiagnaMed Holdings Corp.
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It has a collaboration agreement with EIREX for the development and commercialization of EIREX’s novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdings Corp. is headquartered in Toronto, Canada.
Technical Analysis
Diagnos
―
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―